<DOC>
	<DOC>NCT02508805</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy and safety of Neuromultivit (solution for injections) in treatment of vertebrogenic radiculopathy L5, S1 in comparison with standard therapy. The patients are randomised into two groups: standard therapy group and standard therapy plus Neuromultivit group.</brief_summary>
	<brief_title>Safety and Efficacy of Neuromultivit in Treatment of Vertebrogenic Radiculopathy</brief_title>
	<detailed_description>Group 1 (50 patients) receive Neuromultivit (2 ml per day, i.m.) for 7 days, then -Neuromultivit (2 ml per day, i.m.) every other day for 10 days and standard therapy for 20 days. Group 2 (50 patients) receive only standard therapy for 20 days. Standard therapy involves: - Voltaren (100 mg prolonged-released film-coated tablets once daily) for 20 days - Sirdalud (2 mg tablets three times a day) for 20 days</detailed_description>
	<mesh_term>Radiculopathy</mesh_term>
	<mesh_term>Diclofenac</mesh_term>
	<mesh_term>Tizanidine</mesh_term>
	<mesh_term>Clonidine</mesh_term>
	<criteria>diagnosed vertebrogenic radiculopathy L5, S1 radicular pain syndrome changes in the low back CT and MRI scans minimum 40 mm intensity of spontaneous back pain, rated on the VA scale 1 month exacerbation phase; nonuse of any Bgroup vitamins before the trial negative urine pregnancy test; Patient Informed Consent tumors, inflammatory infections, any neurological diseases, imitating the symptoms of radiculopathy concomitant lifethreatening medical conditions simultaneous administration of acetylsalicylic acid, levodopa, prednisolone; any psychiatric diseases epilepsy, alcohol and drug addiction pregnancy and breastfeeding any condition preventing CT and MRI tests, including obesity and special devices participation in any other clinical study 1 month before enrollment.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>